This trial is active, not recruiting.

Condition telangiectasia, hereditary hemorrhagic
Sponsor Imperial College London
Trial size 100 participants
Trial identifier NCT00733629, IC/CLS4


Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to culture endothelial cells from patients with HHT, to culture cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in different conditions and anticipate that DNA, mRNA and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and ALK-1. We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients with hereditary haemorrhagic telangiectasia and family members Exclusion Criteria: - Unable to provide informed consent

Additional Information

Official title In Vitro Studies pf Endothelial Cells Derived From HHT Patients
Principal investigator Claire L Shovlin
Trial information was received from ClinicalTrials.gov and was last updated in August 2008.
Information provided to ClinicalTrials.gov by Imperial College London.